Ursodeoxycholic acid in primary biliary cirrhosis: Reply  by Beuers, Ulrich & Trauner, Michael
control groups and thus data interpretation should be
madewith great caution [1]. In the asymptomatic PBC co-
hort described by Prince et al. (only 7% of patients were
takingUDCA), 45%did not develop a liver-related symp-
tom during a median follow-up of 7.4 years [7]. These
could be the same patients who “respond” to UDCA.
Moreover, the emphasis in the guidelines for evidence
of histological improvement is misplaced, as we have
previously pointed out [8]. Notably, in the original trials
there were patients in the non-ﬁbrotic stages of PBC
progressing to ﬁbrosis, despite an improvement in
inﬂammation [3,4]. This dichotomy between improve-
ment in inﬂammation but worsening of ﬁbrosis is diﬃ-
cult to interpret as an improvement in histological stage.
In conclusion, the absence of best-level evidence con-
ﬁrms that UDCA for all PBC patients remains an unre-
solved issue. Currently, the highest level of evidence
(meta-analysis of randomized trials) suggests that
UDCA does not inﬂuence patients’ survival, time to
transplantation, or any other patient-important clinical
outcome [3,4].
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We thank Dr. Tsochatzis et al. for their comments. In
the EASL Clinical Practice Guidelines (CPG), we
discussed in detail relevant data available to provide a
balanced discussion of the pro’s and con’s of ursodeoxy-
cholic acid (UDCA) treatment in primary biliary cirrho-
sis (PBC) [1]. Tsochatzis et al. address the diﬃculty of
ﬁnding a long-term beneﬁt of medical treatment particu-
larly in patients in the early stages of a slowly progressive
disease which usually has a course of up to two decades
[1,2]. We agree with the authors that additional data on
the use of UDCA in asymptomatic, early-stage PBC
would be most welcome to further support the beneﬁcial
long-term eﬀect of UDCA in early PBC. In clinical prac-
tice, however, it appears impossible (in light of the data
currently available) to perform high-quality randomized,
placebo-controlled trials over a period of one to two dec-
ades in a cohort of well-informed early-stage patients
large enough to demonstrate a clear-cut survival beneﬁtalso in this subgroup. Therefore, the data presented from
the most recent studies of cohorts followed for a period
of at least a decade [3–5] appeared of value to us when
we recommended medical treatment of early-stage dis-
ease with UDCA [1].
A careful analysis of the available data deriving
from randomized controlled trials of high-quality suggest
that also in early-stage PBC, UDCA led not only to
improvement of biochemicalmarkers including surrogate
markers of survival, but also halted progression of histo-
logical stage. The Spanish randomized, placebo-con-
trolled multicenter trial was the ﬁrst large high-quality
study which addressed this issue by including only pa-
tients with stage 1–3 disease [6] and carefully following
them over a median period of 3.4 years to guarantee
adequate compliance (a factor which often receives inad-
equate attention and deserves consideration when dis-
cussing the dichotomy of short-term improvement of
biochemical markers and inﬂammation, but worsening
1086 Letters to the Editor / Journal of Hepatology 51 (2009) 1082–1090of ﬁbrosis). Interestingly, in this carefully followed Span-
ish cohort, histological progression was clearly halted by
UDCA treatment in comparison to placebo [6].
In contrast to this high-quality randomized, placebo-
controlled trial, meta-analyses which include trials with a
duration of up to two years for a disease with an esti-
mated duration of up to two decades may be suited to
analyze short-term biochemical eﬀects of medical treat-
ment, but certainly carry the risk of diluting the informa-
tion needed for a well-based long-term survival analysis.
The attempts of others [7,8] to provide meta-analyses
which included long-term randomized, placebo-con-
trolled trials for survival analysis only to avoid this dilu-
tive eﬀect may deserve mentioning here; these authors [7]
concluded that long-term treatment with mid-dose
UDCA can improve liver biochemistry, delay histologi-
cal progression in early-stage disease and improve sur-
vival-free of liver transplantation. We have to keep in
mind that meta-analyses are only as good as the trials
they include and have to be judged with some caution [9].
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To the Editor:
In their recent paper Buti and colleagues [1] claim to
have performed a “cost-eﬀectiveness analysis of diﬀerent
oral antiviral therapies in patients with chronic hepatitis
B”, but they did so presenting credible results in an inap-
propriate and potentially misleading manner.
By deﬁnition incremental cost-eﬀectiveness ratio re-
lates to incremental eﬀectiveness put in relation to incre-
mental cost. Therefore, the natural referent alternative
for “oral antiviral therapies” is a therapy in which no
antiviral therapy is used, what Buti and colleagues refer
to as “no treatment”. Indeed Buti and colleagues [1] con-
ceptually appraised decremental, rather than incremental,
cost-eﬀectiveness ratio, by unconventionally taking as a
reference the point estimate “most eﬃcacious treat-
ment”. This is not a standard procedure in cost-eﬀective-
ness analyses. Consequently, the study would be much
more informative presenting the incremental cost of
(each) antiviral therapy compared to “no treatment” inlong-term prognosis in primary biliary cirrhosis. Hepatology
2008;48:871–877.
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ns should be avoided
relation to its incremental eﬀectiveness. This is the stan-
dard approach widely adopted by public health technol-
ogy assessment agencies. This approach has several
advantages: (1) it informs decision makers on ICER
(Incremental Cost-Eﬀectiveness Ratio) of the various
technologies, individually, that can be used compared
to no treatment; (2) it does not require the use of a
sophisticated model that would be needed to detect a
meaningful and signiﬁcant diﬀerence between active
treatments; (3) it does not require problematic and
sophisticated adjustments for diﬀerential characteristics
of patients included in RCT’s (Randomized Clinical
Trial) of diﬀerent active treatments (e.g. diﬀerent base-
line viral load, diﬀerences in tolerability proﬁle), which
are required when (indirect) comparisons between active
treatments are made. A careful reading of the paper by
Buti and colleagues [1] conﬁrms that the model seems
to make accurate and discriminating predictions of costs
and outcomes when “no treatment” on one side and
